Back HCV Populations People Who Inject Drugs

EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains

People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.

alt

Read more:

AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C

A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest Phase 3 trial to date of interferon-free treatment for people with hepatitis C virus genotype 4, according to study findings presented at the 2015 AASLD Liver Meeting taking place this week in San Francisco.

alt

Read more:

AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs

Merck's grazoprevir/elbasvir coformulation demonstrated an overall sustained response rate of 92% for injection drug users receiving opioid substitution therapy in the C-EDGE CO-STAR study, according to a presentation at the 2015 AASLD Liver Meeting taking place this week in San Francisco. Participants maintained good adherence and had a high cure rate even though many continued to use illicit drugs.

alt

Read more:

More Articles...